Weight-loss jabs used as ‘quick fix’
A Danish study of 77,310 semaglutide users found younger and low-income individuals are more likely to stop treatment within a year due to cost and side effects.
- Using nationwide Danish registries, investigators found over half of 77,310 first-time users in Denmark stopped semaglutide within one year.
- Younger people aged 18–29 were 48% more likely to quit semaglutide within a year than adults aged 45–59, and those in low-income areas were 14% more likely, with cost emerging as a key driver.
- Clinical history mattered, with people with a history of psychiatric medications 12% more likely and previous gastrointestinal medication users 9% more likely to discontinue within the first year.
- Thomsen added that stopping treatment undermines benefits, especially as long-term adherence is crucial for people with obesity-related comorbidities.
- High costs—about $1,400 monthly in the U.S. if uninsured and €2,350 annually in Denmark—may widen disparities, despite GLP-1RAs' effectiveness, said Professor Thomsen.
28 Articles
28 Articles

Half Of Ozempic Weight-Loss Users Drop The Drug Within A Year
Key Takeaways
Most quit breakthrough weight-loss drug within a year
A massive Danish study reveals that despite the remarkable weight-loss benefits of semaglutide, more than half of adults without diabetes stop using it within a year. High costs, unpleasant side effects, and underlying medical or psychiatric conditions play major roles in the dropouts. Younger users and men are especially prone to quitting, raising concerns since discontinuation often leads to weight regain.
Weight-loss injections produce rapid results. However, there's a catch: treatment must be continued long-term, otherwise there's a risk of weight quickly returning to "normal." Danish scientists are now presenting an alarming analysis of Wegovy's product.
Coverage Details
Bias Distribution
- 38% of the sources lean Left, 38% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium